News
-
According to US-based ARS Pharmaceuticals, the company has raised $20 million in Series C financing for clinical development of its ARS-1 epinephrine nasal spray for the treatment of anaphylaxis. The financing round was led by… Read more . . .
-
AOBiome Therapeutics, which is developing several intranasal ammonia oxidizing bacteria (AOB) candidates, said that Judith Ng-Cashin was appointed Chief Medical Officer as of October 1, 2018. Ng-Cashin was most recently Chief Scientific Officer at Syneos… Read more . . .
-
Canadian life science fund AmorChem has announced the launch of MyX Therapeutics, which will focus on development of drugs formulated with MyX-001 mucoadhesive nanoparticle delivery platform, with a $450,000 seed investment. MyX-001 is based on… Read more . . .
-
Verona Pharma said that it has initiated a Phase 2 clinical trial of its RPL554 PDE3/PDE4 inhibitor DPI. The study is expected to enroll 36 patients with moderate to severe COPD and will evaluate PK,… Read more . . .
-
Insys Therapeutics says that it plans NDA submissions for both its naloxone and epinephrine nasal sprays in 2019. The company also noted the potential of regulatory submission for its inhaled dronabinol in the next few… Read more . . .
-
Pharmaxis said that its distribution partner Methapharm Inc. has begun selling Pharmaxis’ Aridol mannitol bronchial challenge test kit again in the United States. According to the company, its Sydney, Australia manufacturing facility received FDA approval… Read more . . .
-
Finnish nanotechnology company Nanoform has announced construction of a new 600m2 GMP manufacturing facility at Viikki Life Science Park in Helsinki. The plant, which is expected to be operational sometime in 2019, will result in… Read more . . .
-
According to Levo Therapeutics, the Phase 3 CARE-PWS (CARbetocin Efficacy and Safety Study in PWS) trial of LV-101 intranasal carbetocin for the treatment of Prader-Willi syndrome (PWS) has begun to enroll patients. Levo acquired the… Read more . . .
-
French device company Biocorp announced that it has signed an agreement with Lindal Group subsidiary VARI under which VARI will incorporate Biocorp’s Inspair inhaler sensor into its devices in a deal that includes exclusivity for… Read more . . .
-
According to Iconovo, Japanese pharmaceutical company TOA Pharmaceuticals has placed a “significant” order for DPIs to be used in a feasibility study. Iconovo will produce two customized versions of the inhaler and will conduct the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.